Brain Lesions After Transcatheter Aortic Valve Replacement

Sponsor
West China Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05065697
Collaborator
St Thomas' Hospital, London (Other), Rigshospitalet, Denmark (Other)
150
24

Study Details

Study Description

Brief Summary

The Brain lEsions after TrAnscatheter aorTic ValvE Replacement (BETTER) registry is a prospective, observational, multi-center registry aiming to assess the presence of new brain microbleeds assessed on susceptibility-weighted imaging at 3 enrolling sites, in China (West China Hospital, Sichuan University), UK (St Thomas' Hospital) and Denmark (Rigshospitalet, University of Copenhagen). The main study arm is planned to include 100 patients with symptomatic severe aortic stenosis undergoing transfemoral TAVR of any devices and 50 isolated bioprosthetic SAVR patients treated during the enrollment period as a control arm.

Condition or Disease Intervention/Treatment Phase
  • Other: Brain MRI

Detailed Description

"Silent" stroke post-TAVR presents as asymptomatic brain ischemic lesions detected on diffusion-weighted magnetic resonance imaging (DW-MRI), with an incidence ranging from 60% to 100% in different studies. On the contrary, hemorrhagic lesions are not systematically studied given the poor visualization of small hemorrhage (i.e. microbleeds) on traditional T1, T2 or DW-MRI sequences. We have previously identified an incidence of new brain microbleeds early after TAVR of 100% with the routine use of susceptibility-weighted imaging (SWI). We hypothesize that new brain microbleeds are prevalent in patients with aortic stenosis after either TAVR or SAVR. The key objective of this registry is to evaluate the incidence, distribution and clinical impact of new brain microbleeds after transfemoral TAVR in patients with symptomatic severe aortic stenosis, in comparison with SAVR.

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Brain Lesions After Transcatheter Aortic Valve Replacement
Anticipated Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
TAVR arm

Symptomatic severe aortic stenosis undergoing transfemoral TAVR of any devices

Other: Brain MRI
Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.
Other Names:
  • Neurological and cognitive assessments as recommended by NeuroARC
  • SAVR arm

    Symptomatic severe aortic stenosis undergoing isolated bioprosthetic surgical aortic valve replacement

    Other: Brain MRI
    Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.
    Other Names:
  • Neurological and cognitive assessments as recommended by NeuroARC
  • Outcome Measures

    Primary Outcome Measures

    1. The incidence of new brain microbleeds detected on MRI [Post-procedurally (up to 7 days) and 6 months]

      Microbleeds (including the number and size) on SWI after TAVR or SAVR during the index hospitalization and their evolution at the follow-up

    2. The incidence of new brain embolisms detected on MRI [Post-procedurally (up to 7 days) and 6 months]

      Ischemic infarcts (including the number and size) on DW-MRI after TAVR or SAVR during the index hospitalization and their evolution at the follow-up

    Secondary Outcome Measures

    1. Changes in the neurological and cognitive status of the patients (see description for specific assessments) [Post-procedurally (up to 7 days), 6 months and 1 year]

      NIH Stroke Scale (NIHSS) and Montreal Cognitive Assessment (MoCA, cognitive impairment = score <23/30) for overall cognitive status, and tests for five individual cognitive domains (Attention: Digit Symbol-Coding test [DSST]; Memory: Hopkins Verbal Learning Test-Revised [HVLT-R], Brief Visual Memory Test-Revised [BVMT-R]; Executive Function: Stroop Color-Word Association Test [SCWT], Category and Verbal Fluency [both semantic and phonemic]; Visuospatial Function: BVMT-R). The change of score in each assessment will be calculated.

    Other Outcome Measures

    1. Perfusion changes on transcranial doppler during TAVR or SAVR (if obtained) [Intra-procedurally]

      Baseline perfusion will be obtained before femoral puncture in TAVR and the start of cardiopulmonary bypass in SAVR, until completion of eventual postimplantation maneuvers in TAVR and the stop of cardiopulmonary bypass in SAVR

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    60 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Symptomatic severe aortic stenosis (>60 years old) being scheduled for either transfemoral TAVR or isolated SAVR
    Exclusion Criteria:
    • Patients who have been diagnosed with brain cancer, brain haemorrhage, brain abscess, aneurysm, cerebral palsy, encephalitis, nervous system infection, head or neurological injury, or trauma, stroke

    • Contraindications for a magnetic resonance imaging (MRI) scan (i.e. metallic implants, claustrophobia, MR-incompatible pacemakers or prosthetic heart valves)

    • Unremovable dental prostheses that are deemed to affect MRI quality

    • Severe coronary artery disease that is unrevascularized

    • Prior stroke within the last 12 months

    • Expected non-compliance concerning follow-up examinations

    • Have participated in other clinical trials

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • West China Hospital
    • St Thomas' Hospital, London
    • Rigshospitalet, Denmark

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mao Chen, Director of Department of Cardiology, West China Hospital
    ClinicalTrials.gov Identifier:
    NCT05065697
    Other Study ID Numbers:
    • 2021V1
    First Posted:
    Oct 4, 2021
    Last Update Posted:
    Jan 13, 2022
    Last Verified:
    Dec 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Mao Chen, Director of Department of Cardiology, West China Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 13, 2022